PROMOGRAN PRISMA™ Matrix

Products described on this website (and associated product information), may not be available for sale in all markets as a result of local regulatory requirements. For information regarding product availability in your market, please contact your local Acelity/KCI representative here.

A Clinically Proven Combination

PROMOGRAN PRISMA™ Matrix is comprised of a sterile, freeze dried composite of 44% oxidized regenerated cellulose (ORC), 55% collagen and 1% silver-ORC. Silver-ORC contains 25% w/w ionically bound silver, a well-known antimicrobial agent.

Optimum wound environment
PROMOGRAN PRISMA™ Matrix, when covered with a semi-occlusive or non-occlusive dressing maintains a physiologically moist microenvironment at the wound surface. This environment is conducive to granulation tissue formation, epithelization and optimal wound healing. What is the role of silver in PROMOGRAN PRISMA™ Matrix? The dressing contains ionically bound silver, a well-known antimicrobial agent. 
 

To order any of the products listed below, please contact your KCI representative or call your local KCI Office. Click here to contact us.


  • Overview
  • How it Works
  • Indications & Applications
  • Evidence & Outcomes
  • Ordering

Overview

Reduction in Wounds Displaying Signs of  Infection


In a 14-week RCT comparing PROMOGRAN PRISMA Matrix (n=25), with Control (n= 15), the number of patients withdrawn from the study due to infection was significantly greater in the control group 0% VS. 31% (p=0.012)1 (n=40) 


79% VS. 43% For the Standard of care (rate of healing was characterized as >50% reduction in wound size)1

Collagen-14-week-study.png

 


 

Economic Value

 

With PROMOGRAN™ Matrix Wound Dressing and PROMOGRAN PRISMA™ Matrix. Read the Economic Value Brochure

 


 

What is ORC?


Cellulose is a major component of all plants. Once oxidized, ORC (Oxidized Regenerated Cellulose) is completely bioresorbable, and readily degrades through fluid absorption and subsequent gelling1

What-is-Collagen.png

 

 

 

 

How it Works

  • ABOUT
  • SPECIFICATIONS
  • MATERIALS FOR DOWNLOAD

Maintains an optimum wound-healing environment

In the presence of exudate, PROMOGRAN PRISMA™ Matrix transforms into a soft, conformable, biodegradable gel, allowing contact with all areas of the wound. 

PROMOGRAN PRISMA™ Matrix, Matrix, when covered with a semi-occlusive dressing, maintains a physiologically moist microenvironment at the wound surface. This environment is conducive to granulation tissue formation, epithelialization and optimal wound healing.

  • Optimum wound environment
  • Clinically proven
Product description 
 
PROMOGRAN PRISMA™ Matrix is a topically applied dressing. The product is a sterile, freeze dried, composite of oxidized regenerated

cellulose (ORC), collagen and silver-ORC, (a compound of Silver and ORC). In the presence of exudate the PROMOGRAN PRISMA™ Matrix transforms

into a soft and conformable, biodegradable gel, this allows contact with all areas of the wound. Saline should be used to hydrate

PROMOGRAN PRISMA Matrix prior to application in dry wounds.

.

Indications & Applications

  • INDICATIONS
  • APPLICATIONS
Specific indications, contraindications, warnings, precautions and safety information exist for KCI products and therapies. Healthcare providers should review the product User Manual, Safety Information and/or Instructions for Use prior to application.

PROMOGRAN™ PRISMA Matrix is indicated for the management of exuding wounds including:

 • Diabetic ulcers

• Venous ulcers
• Pressure ulcers
• Ulcers caused by mixed vascular etiologies
• Full-thickness & partial thickness wounds
• Donor sites and other bleeding surface wounds
• Abrasions
• Traumatic wounds healing by secondary intention
• Dehisced surgical wounds

PROMOGRAN™ PRISMA Matrix is a primary dressing that can be cut to fit the wound with scissors and must be covered with either gauze, a semi-occlusive or non-occlusive secondary dressing in order to maintain a moist wound healing environment.

 

Applications

 

Storage

PROMOGRAN PRISMA™ Matrix should be stored away from direct light. Over-exposure to light may cause some discolouration, however this does not affect the release of silver from the dressing. Store below 25 °C / 77 °F. Prepare wound bed per your standard wound care protocol and debride when necessary.

 

  • For optimal effect, apply PROMOGRAN PRISMA™ Matrix directly to the whole wound bed.
  • For a wound with low or no exudate apply PROMOGRAN PRISMA™ Matrix and hydrate with saline. This will initiate the gel forming process.
  • After hydration the PROMOGRAN PRISMA™ Matrix gel will intimately contact the wound
  • The biodegradable gel is naturally absorbed over time.

Prepare wound bed per your standard wound care protocol and debride when necessary.
For optimal effect, apply PROMOGRAN PRISMA™ Matrix directly to the whole wound bed.
  • For a wound with low or no exudate apply PROMOGRAN PRISMA™ Matrix and hydrate with saline solution. This will initiate the transformation of the PROMOGRAN
    PRISMA™ Matrix into a gel.
  • After hydration, through exposure to wound exudate or saline, the PROMOGRAN PRISMA™ Matrix gel will intimately come into contact with the wound surface.
  • The biodegradable PROMOGRAN PRISMA™ Matrix gel is naturally absorbed into the body over time.
  • In order to maintain a moist wound healing environment PROMOGRAN PRISMA™ Matrix must be covered with a semi-occlusive dressing (e.g. BIOCLUSIVE ™ Plus Transparent Film Dressing, TIELLE™ Hydropolymer Dressing or TIELLE™ Plus Hydropolymer Dressing) or a non-occlusive secondary dressing and fixed to the skin with a non-irritating tape.
  • After initial application, reapply PROMOGRAN PRISMA™ Matrix to the wound daily or per physician recommendation. It is not necessary to remove any residual PROMOGRAN PRISMA™ Matrix during dressing changes.

Evidence & Outcomes

The efficacy of PROMOGRAN PRISMA™ Matrix is supported by clinical evidence, including 2 published RCTs1,2. Acelity Clinical Evidence is a resource for healthcare professionals to explore preclinical, clinical, and review articles discussing the use of Acelity™ products. 

 

Clinical Evidence

Additional summary of evidence and outcomes.

Contact Us

TITLE Randomized comparative trial of a collagen/oxidized regenerated cellulose dressing in the treatment of neuropathic diabetic foot ulcers]. Cirugia Espanola. 2007 Jul;82(1):27-31.
View Abstract on PubMed
STUDY TYPE All levels
DATE 2007
AUTHORS Lazaro-Martinez JL, et al.
TITLE Can natural materials be adapted to optimize their efficiency in wound care?
View Abstract on PubMed
STUDY TYPE All levels
DATE 2014
AUTHORS Gibson M, et al.
TITLE The benefits of oxidised regeneratThe ed cellulose for wound healing. Presented at wound UK harrogate 2011, November 14-16, 2011, Harrogate, UK
View Abstract on PubMed
STUDY TYPE All levels
DATE 2004
AUTHORS Cullen B, et al.
TITLE Effect of oxidized regenerated cellulose/collagen matrix on proteases in wound exudate of patients with diabetic foot ulcers. Journal of Wound, Ostomy, and Continence Nursing. 2011 Sep-Oct;38(5):522-8.
View Abstract on PubMed
STUDY TYPE All levels
DATE 2011
AUTHORS Ulrich D, et al.
TITLE An in vitro model to evaluate the ability of collagen/ORC/silver to absorb components of wound exudate and reduce inflammatory protease activity compared with other dressings.
View Abstract on PubMed
STUDY TYPE All levels
DATE 2011
AUTHORS Gibson M, et al.
TITLE Modulation of the chronic wound environment; an in vitro evaluation of advanced wound therapies. Presented at the Symposium on Advanced Wound Care, April 28-May 1, 2007, Tampa, FL
View Abstract on PubMed
STUDY TYPE All levels
DATE 2007
AUTHORS Cullen B, et al.
TITLE Managing the wound environment using collagen/ORC/ silver dressing
View Abstract on PubMed
STUDY TYPE All levels
DATE 2010
AUTHORS Cullen B, et al.
TITLE Clinical experiences derived from implementation of an easy to use concept for treatment of wound healing by secondary intention and guidance in selection of appropriate dressings
View Abstract on PubMed
STUDY TYPE All levels
DATE 2011
AUTHORS Braumann, et al.
TITLE Collagen-based wound dressings for the treatment of diabetes-related foot ulcers: a systematic review
View Abstract on PubMed
STUDY TYPE All levels
DATE 2013
AUTHORS Holmes, et al.
TITLE The role of oxidised regenerated cellulose/collagen in wound repair: effects in vitro on fibroblast biology and in vivo in a model of compromised healing. International Journal of Biochemistry and Cell Biology. 2002 Dec 1;34(12):1557-1570
View Abstract on PubMed
STUDY TYPE All levels
DATE 2002
AUTHORS Hart J, et al.
TITLE A retrospective study of sequential therapy with advanced wound care products versus saline gauze dressings: comparing healing and cost
View Abstract on PubMed
STUDY TYPE All levels
DATE 2010
AUTHORS Snyder, et al.
TITLE http://onlinelibrary.wiley.com/doi/10.1111/wrr.12020/abstract
View Abstract on PubMed
STUDY TYPE All levels
DATE 2013
AUTHORS Gottrup, et al.
TITLE THE ROLE OF PROMOGRAN IN REBALANCING THE WOUND ENVIRONMENT AND ITS EFFECT ON HEALING: 547. Shock, 2004
View Abstract on PubMed
STUDY TYPE All levels
DATE 2004
AUTHORS Cullen B, et al.
TITLE Prospective and randomised evaluation of the protease-modulating effect of oxidised regenerated cellulose/collagen matrix treatment in pressure sore ulcers.International Wound Journal. 2015 May 23
View Abstract on PubMed
STUDY TYPE All levels
DATE 2011
AUTHORS Kloeters O, et al. 
TITLE A pilot randomised trial to determine the effects of a new active dressing on wound healing of venous leg ulcers
View Abstract on PubMed
STUDY TYPE All levels
DATE 2008
AUTHORS Lanzara, et al.
TITLE A retrospective study of sequential therapy with advanced wound care products versus saline gauze dressings: Comparing healing and cost.
View Abstract on PubMed
STUDY TYPE All levels
DATE 2010
AUTHORS Snyder, et al.
TITLE Expression of matrix-metalloproteases in the fluid of chronic diabetic foot wounds treated with a protease absorbent dressing. Experimental and Clinical Endocrinology and Diabetes. 2011 May;119(5):286-90. Epub 2010 Oct 28
View Abstract on PubMed
STUDY TYPE All levels
DATE 2012
AUTHORS Motzkau M, et al.
TITLE Effect of oxidised regenerated cellulose/collagen matrix on proteases in wound exudate of patients with chronic venous ulceration. International Wound Journal. 2008 Jun;5(2):195-203.
View Abstract on PubMed
STUDY TYPE All levels
DATE 2008
AUTHORS Smeets R, et al.

To order any of the products listed below, please contact your KCI representative or call your local KCI Office. Click here to contact us.

 

  • PROMOGRAN PRISMA™ Matrix

    PRODUCT PRODUCT CODE   dressings per box
     
    FS-380x380-promogran-prisma-packs.jpg

    PROMOGRAN PRISMA™ Matrix

    4.34 sq. in. Hexagon

     
     
     MA028  
    Box of 40 (4 Cartons of 10)
    HCPCS Code A6021
     
    FS-380x380-promogran-front.jpg

    PROMOGRAN PRISMA™ Matrix

    19.1 sq. in. Hexagon


     MA123  
    Box of 40 (4 Cartons of 10)
    HCPCS Code A6022